etoposide,doxorubicin,rituximab
Roche
['lymsm', 'lymphoma']
rcodox-m/r-ivac vs daepoch-r in high risk burkitt lymphoma underpowered trial that closed early but: similar pfs, os, cmr rate in both arms less toxicity with daepoch: fewer admissions, less infections, fewer transfusions
valuable data #lymsm #eha2022 
#Lymphoma #CLL specialist @OUHospitals
Hon. senior lecturer @UniofOxford
Low grade+elderly high grade UK NCRI grp member
UK #CLL forum exec committee 
#lymsm